| Literature DB >> 35987613 |
Qiangdong Wang1, Yan Jiang2, Mulong Du3, Lei Yang4, Qinbo Yuan5.
Abstract
Trefoil Factor 1 (TFF1) is considered to be able to inhibit the formation of kidney stone. However, genetic variants in TFF1 and corresponding function in kidney stone development are still not well studied. In this study, the discovery set including 230 cases and 250 controls was used to analyze the association between seven tagSNPs of TFF1 gene and the nephrolithiasis risk. Further evaluation was confirmed by the validation set comprising 307 cases and 461 controls. The consequences of the two-stage case-control study indicated that individuals with the rs3761376 A allele have significantly increased nephrolithiasis risk than those with the GG genotypes [adjusted odds ratio (OR) = 1.35, 95% confidence interval (CI) = 1.05-1.73]. Moreover, we also carried out a stratified analysis and found the increased nephrolithiasis risks at A allele among males, overweight individuals, no hypertensive individuals, nondiabetic individuals, smokers, and drinkers. In the following functional experiments, the notably lower expression of TFF1 was exhibited by the vectors carrying A allele compared with those carrying G allele in both luciferase (P = 0.022) and expression vectors (P = 0.041). In addition to tissue detection, we confirmed a significant inverse association of rs3761376 G > A and TFF1 gene expression (P < 0.001). These results suggest that TFF1 rs3761376 may serve as a potential biomarker to predict the risk of nephrolithiasis.Entities:
Keywords: Nephrolithiasis; Risk factors; Single nucleotide polymorphism; TFF1
Mesh:
Substances:
Year: 2022 PMID: 35987613 PMCID: PMC9392923 DOI: 10.1186/s12894-022-01081-w
Source DB: PubMed Journal: BMC Urol ISSN: 1471-2490 Impact factor: 2.090
The distribution of the demographic characteristics of combined set
| Variables | Cases, n = 537 | Controls, n = 711 | |
|---|---|---|---|
| Mean age ± SD, years | 48.0 ± 13.2 | 46.1 ± 9.4 | |
| ≤ 46, n (%) | 243 (45.3) | 243 (53.0) | |
| > 46, n (%) | 294 (54.7) | 218 (47.0) | |
| Gender, n (%) | 0.656 | ||
| Male | 363 (67.7) | 473 (66.5) | |
| Female | 173 (32.3) | 238 (33.5) | |
| Body mass index, n (%) | 0.113 | ||
| ≤ 24 | 231 (45.5) | 356 (50.1) | |
| > 24 | 277 (54.5) | 355 (49.9) | |
| Hypertension, n (%) | |||
| Yes | 144 (27.8) | 130 (18.3) | |
| No | 374 (72.2) | 580 (81.7) | |
| Diabetes, n (%) | 0.934 | ||
| Yes | 30 (5.8) | 42 (5.9) | |
| No | 487 (94.2) | 668 (94.1) | |
| Smoking status, n (%) | |||
| Ever | 221 (41.5) | 215 (30.3) | |
| Never | 312 (58.5) | 495 (69.7) | |
| Drinking status, n (%) | 0.996 | ||
| Ever | 188 (35.3) | 251 (35.4) | |
| Never | 344 (64.7) | 459 (64.6) |
Bold font indicates P values < 0.05, which were statistically significant
aP-value for two-sided χ2 test. SD, standard deviation
Association of TFF1 and nephrolithiasis risk in each stage
| Stage | tagSNPs | Alleles (major/minor) | Casesa | Controlsa | Adjusted OR (95% CI)b | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Co-dominant model | Additive model | Dominant model | Recessive model | |||||||||
| Hetb | Homb | |||||||||||
| Discovery | rs225355 | G > A | 147/72/11 | 151/93/6 | 0.74 (0.50–1.09) | 2.00 (0.70–5.75) | 0.81 (0.55–1.18) | 0.81 (0.55–1.18) | 2.23 (0.78–6.34) | 0.268 | 1.000 | 0.185 |
| rs2839488 | C > G | 129/79/19 | 147/86/16 | 1.01 (0.68–1.51) | 1.50 (0.72–3.10) | 1.12 (0.84–1.51) | 1.08 (0.74–1.57) | 1.49 (0.73–3.04) | 0.433 | 1.000 | 0.594 | |
| rs13051704 | C > G | 140/63/10 | 131/107/12 | 0.70 (0.29–1.73) | 0.90 (0.37–2.17) | 0.056 | ||||||
| rs225358 | C > T | 128/82/20 | 143/79/28 | 1.21 (0.81–1.81) | 0.82 (0.43–1.56) | 1.01 (0.76–1.32) | 1.11 (0.77–1.61) | 0.77 (0.41–1.43) | 0.969 | 1.000 | 0.499 | |
| rs3761376 | G > A | 64/112/51 | 100/117/33 | 1.47 (0.97–2.23) | ||||||||
| rs225359 | G > A | 121/90/19 | 144/84/22 | 1.36 (0.92–2.02) | 1.05 (0.53–2.07) | 1.15 (0.86–1.53) | 1.30 (0.90–1.88) | 0.93 (0.48–1.80) | 0.335 | 1.000 | 0.451 | |
| rs35448902 | C > T | 151/65/11 | 140/97/13 | 0.72 (0.30–1.69) | 0.84 (0.36–1.96) | 0.301 | ||||||
| Validation | rs3761376 | G > A | 108/123/66 | 186/214/61 | 0.97 (0.69–1.36) | 1.16 (0.85–1.59) | ||||||
| Combined | rs3761376 | G > A | 172/235/117 | 286/331/94 | 1.15 (0.88–1.51) | |||||||
Bold font indicates P values < 0.05, which were statistically significant
aMajor homozygote/heterozygote/rare homozygote between cases and controls
bLogistic regression model with adjustment for age, sex, hypertension and smoking status in co-dominant (het: heterozygote vs. major homozygote; hom: rare homozygote vs. major homozygote), additive (rare homozygote vs. heterozygote vs. major homozygote), dominant (heterozygote/rare homozygote vs. major homozygote), recessive (rare homozygote vs. heterozygote / major homozygote) models; OR, odds ratio; CI, confidence interval
cP for additive model
dPadj adjusted by Bonferroni correction
Stratified analyses on the association between TFF1 rs3761376 and nephrolithiasis risk
| Characteristic | Cases (n = 537), n (%) | Controls (n = 711), n (%) | OR (95% CI)a | |||||
|---|---|---|---|---|---|---|---|---|
| GG | AG + AA | GG | AG + AA | |||||
| Age, years | 0.744 | 0.152 | ||||||
| ≤ 46 | 73 (30.8) | 164 (69.2) | 151 (40.1) | 226 (59.9) | 1.44 (0.98–2.10) | 0.062 | ||
| > 46 | 99 (34.5) | 188 (65.5) | 135 (40.4) | 199 (59.6) | 1.32 (0.92–1.88) | 0.135 | ||
| Gender | 0.806 | 0.562 | ||||||
| Male | 109 (30.6) | 247 (69.4) | 183 (38.7) | 290 (61.3) | ||||
| Female | 63 (37.5) | 105 (62.5) | 103 (43.3) | 135 (56.7) | 1.61 (0.73–1.85) | 0.528 | ||
| BMI, mg/k2 | 0.392 | 0.345 | ||||||
| ≤ 24 | 78 (34.7) | 147 (65.3) | 144 (40.4) | 212 (59.6) | 1.24 (0.86–1.79) | 0.241 | ||
| > 24 | 80 (29.3) | 193 (70.3) | 142 (40.0) | 213 (60.0) | ||||
| HP | 0.981 | 0.823 | ||||||
| Yes | 45 (31.5) | 98 (68.5) | 47 (36.2) | 83 (63.8) | 1.36 (0.80–2.30) | 0.255 | ||
| No | 122 (33.6) | 241 (66.4) | 238 (41.0) | 342 (59.0) | ||||
| Diabetes | 0.968 | 0.882 | ||||||
| Yes | 13 (43.3) | 17 (56.7) | 20 (47.6) | 22 (52.4) | 1.37 (0.47–3.98) | 0.562 | ||
| No | 152 (32.0) | 323 (68.0) | 265 (39.7) | 403 (60.3) | ||||
| Smoking status | 0.237 | 0.484 | ||||||
| Ever | 64 (29.6) | 152 (70.4) | 82 (38.1) | 133 (61.9) | ||||
| Never | 107 (35.2) | 197 (64.8) | 203 (41.0) | 292 (59.0) | 1.22 (0.90–1.66) | 0.203 | ||
| Drinking status | ||||||||
| Ever | 49 (26.8) | 134 (73.2) | 105 (41.8) | 146 (58.2) | ||||
| Never | 122 (36.3) | 214 (63.7) | 180 (39.2) | 279 (60.8) | 1.06 (0.78–1.44) | 0.733 | ||
Bold font indicates P values < 0.05, which were statistically significant
aAdjusted for age, sex, hypertension and smoking status as appropriate in the logistic regression model; BMI, body mass index; HP, hypertension
Fig. 1Luciferase activity affected by rs3761376. Different luciferase reporter vectors with either rs3761376 allele (G or A) which included the sequence of the promoter of TFF1 were transfected into HEK-293 cells. Then, the luciferase activity was detected and normalized by the internal control of Renilla luciferase
Fig. 2Transcriptional activity affected by rs3761376. Different expression vectors with either rs3761376 allele (G or A) which included the sequence of the promoter of TFF1 were transfected into HEK-293 cells. Then, the transcriptional activity was detected by real-time PCR
Fig. 3Correlation between different rs3761376 genotypes and TFF1 expression